These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1353691)

  • 21. (S)-amisulpride as a discriminative stimulus in C57BL/6 mice and its comparison to the stimulus effects of typical and atypical antipsychotics.
    Donahue TJ; Hillhouse TM; Webster KA; Young R; De Oliveira EO; Porter JH
    Eur J Pharmacol; 2014 Jul; 734():15-22. PubMed ID: 24726559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect.
    Marchese G; Ruiu S; Casti P; Bartholini F; Saba P; Gessa GL; Pani L
    Eur J Pharmacol; 2002 Jun; 447(1):109-14. PubMed ID: 12106810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amisulpride-induced hyperprolactinemia is reversible following discontinuation.
    Paparrigopoulos T; Liappas J; Tzavellas E; Mourikis I; Soldatos C
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):92-6. PubMed ID: 16938372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of tiapride on the activity of neuroleptics and other kinds of drugs in mice and rats].
    Satoh H; Terai T; Nakanishi H; Ono T; Shibayama F
    Nihon Yakurigaku Zasshi; 1988 Feb; 91(2):71-80. PubMed ID: 2897321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The features of atypical neuroleptic amisulpride action].
    Grigor'eva EA; Ritskov AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(6):59-64. PubMed ID: 15285638
    [No Abstract]   [Full Text] [Related]  

  • 26. Consensus on the use of substituted benzamides in psychiatric patients.
    Racagni G; Canonico PL; Ravizza L; Pani L; Amore M
    Neuropsychobiology; 2004; 50(2):134-43. PubMed ID: 15292667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality.
    Möller HJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1101-11. PubMed ID: 14642970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioral pharmacology of the benzamides as compared to standard neuroleptics.
    Worms P
    Adv Biochem Psychopharmacol; 1982; 35():7-16. PubMed ID: 6128876
    [No Abstract]   [Full Text] [Related]  

  • 29. The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved?
    Baptista T; Lacruz A; Pàez X; Hernàndez L; Beaulieu S
    Eur J Pharmacol; 2002 Jun; 447(1):91-8. PubMed ID: 12106808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amisulpride: a review of its use in the management of schizophrenia.
    Curran MP; Perry CM
    Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The discriminant dopamine antagonist property of benzamides is observed at various times after their systemic or intracerebroventricular administration.
    Protais P; Hermier C; Costentin J
    Neuropharmacology; 1985 Sep; 24(9):861-7. PubMed ID: 2865694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of sultopride on prolactin secretion in rats.
    Mizuchi A; Kitagawa N; Saruta S; Tokuda H; Miyachi Y
    Arch Int Pharmacodyn Ther; 1984 Feb; 267(2):232-40. PubMed ID: 6424592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (-)S amisulpride binds with high affinity to cloned dopamine D(3) and D(2) receptors.
    Castelli MP; Mocci I; Sanna AM; Gessa GL; Pani L
    Eur J Pharmacol; 2001 Dec; 432(2-3):143-7. PubMed ID: 11740949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring.
    Sparshatt A; Taylor D; Patel MX; Kapur S
    Acta Psychiatr Scand; 2009 Dec; 120(6):416-28. PubMed ID: 19573049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is amisulpride an 'atypical' atypical antipsychotic agent?
    Lecrubier Y
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of SCH 23390, a D-1-selective antagonist, with the anterior pituitary D-2 receptors and prolactin secretion in the rat.
    Apud JA; Masotto C; Ongini E; Racagni G
    Eur J Pharmacol; 1985 Jun; 112(2):187-93. PubMed ID: 2863153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antipsychotic substances and dopamine in the rat brain; behavioral studies reveal distinct dopamine receptor systems.
    Van Ree JM; Elands J; Király I; Wolterink G
    Eur J Pharmacol; 1989 Aug; 166(3):441-52. PubMed ID: 2572429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study.
    la Fougère C; Meisenzahl E; Schmitt G; Stauss J; Frodl T; Tatsch K; Hahn K; Möller HJ; Dresel S
    J Nucl Med; 2005 Jun; 46(6):1028-33. PubMed ID: 15937316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion.
    Roix JJ; DeCrescenzo GA; Cheung PH; Ciallella JR; Sulpice T; Saha S; Halse R
    Diabetes Obes Metab; 2012 Apr; 14(4):329-34. PubMed ID: 22059694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parallelism between avoidance-suppressing and prolactin-increasing effects of antipsychotic drugs in rats.
    Hayashi T; Tadokoro S
    Jpn J Pharmacol; 1984 Aug; 35(4):451-6. PubMed ID: 6150130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.